Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05611905 · ClinicalTrials.gov registry record
Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid
A clinical trial, sponsored by Johns Hopkins University.
- Completed
- Registry status
- 13
- Enrollment target
NCT05611905: Completed study, sponsored by Johns Hopkins University.
NCT05611905 is a clinical trial that has completed, run by Johns Hopkins University. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05611905 has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- 13 participants
- Enrollment target
Study Summary
The investigators will perform radionuclide PET scans in subjects with infectious diseases to assess whether radio-labeled PABA (11C-PABA) is effective for infection imaging. Tomographic imaging can be used to evaluate disease processes deep within the body, noninvasively and relatively rapidly. The goal is to see if this imaging technique can help differentiate infections from non-infectious processes and also provide information on the causative bacterial class.
Primary Outcome
Reconstruction of the PET data will be performed by means of iterative reconstruction (IR) by the ordered subset-expectation-maximization (OSEM) method with CT attenuation correction.
Interventions
- DRUG Probenecid
- COMBINATION_PRODUCT 11C-para-aminobenzoic acid PET/CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2023-12-22 |
| Est. Completion | 2025-11-08 |
What the finished NCT05611905 record still lists
NCT05611905 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Probenecid is the first listed.
NCT05611905 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05611905 about?
NCT05611905 is a clinical study titled "Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid". The investigators will perform radionuclide PET scans in subjects with infectious diseases to assess whether radio-labeled PABA (11C-PABA) is effective for infection imaging. Tomographic imaging can be used to evaluate disease processes deep within the body, noninvasively and relatively rapidly. Th...
What is the current status of trial NCT05611905?
This trial is currently completed. The enrollment target is 13 participants. The study started on 2023-12-22. Estimated completion is 2025-11-08.
What interventions are being tested in trial NCT05611905?
The interventions under investigation include: Probenecid (DRUG), 11C-para-aminobenzoic acid PET/CT (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05611905?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI